Back to News
Market Impact: 0.3
What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechProduct LaunchesRegulation & Legislation
Agios Pharmaceuticals reported record third-quarter product revenue as AQVESME continued its U.S. launch for thalassemia. The company is also preparing for a delayed regulatory decision on AQVESME’s use in sickle cell disease; the article provides no revenue figures or revised decision date.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.15
Ticker Sentiment
AGIO0.55
More News
- Truist cuts Agios Pharma stock price target on SCD concerns
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- South Korea’s KOSPI halts trade after 8% wipeout on AI losses
- U.S. stock futures rise after AI rout batters Wall St; payrolls data in focus